Medlab Clinical Limited engages in the sale of nutraceutical products, and pharmaceutical research and commercialization in Australia.
+ 1 more risk
Adequate balance sheet and overvalued.
Share Price & News
How has Medlab Clinical's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: MDBB.F has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: Insufficient data to determine how MDBB.F performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how MDBB.F performed against the US Market.
Price Volatility Vs. Market
How volatile is Medlab Clinical's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Medlab Clinical undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate MDBB.F's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate MDBB.F's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: MDBB.F is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: MDBB.F is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MDBB.F's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MDBB.F is good value based on its PB Ratio (3.7x) compared to the US Biotechs industry average (3.7x).
How is Medlab Clinical forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Medlab Clinical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine Medlab Clinical's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Medlab Clinical's filings and announcements here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has Medlab Clinical performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MDBB.F is currently unprofitable.
Growing Profit Margin: MDBB.F is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MDBB.F is unprofitable, and losses have increased over the past 5 years at a rate of -28.8% per year.
Accelerating Growth: Unable to compare MDBB.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MDBB.F is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).
Return on Equity
High ROE: MDBB.F has a negative Return on Equity (-91.74%), as it is currently unprofitable.
How is Medlab Clinical's financial position?
Financial Position Analysis
Short Term Liabilities: MDBB.F's short term assets (A$15.5M) exceed its short term liabilities (A$4.3M).
Long Term Liabilities: MDBB.F's short term assets (A$15.5M) exceed its long term liabilities (A$2.3M).
Debt to Equity History and Analysis
Debt Level: MDBB.F's debt to equity ratio (4.7%) is considered satisfactory.
Reducing Debt: MDBB.F's debt to equity ratio has reduced from 10.5% to 4.7% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MDBB.F has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: MDBB.F has less than a year of cash runway if free cash flow continues to reduce at historical rates of 28.1% each year
What is Medlab Clinical's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MDBB.F's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MDBB.F's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MDBB.F's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MDBB.F's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MDBB.F's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Dr. Sean Michael Hall serves as the Chief Executive Officer and Managing Director of Medlab Clinical Limited. Dr. Hall started Medlab in August 2012. Dr. Hall has over 20 years of experience in the Austral ...
CEO Compensation Analysis
Compensation vs Market: Sean's total compensation ($USD222.08K) is below average for companies of similar size in the US market ($USD593.36K).
Compensation vs Earnings: Sean's compensation has increased whilst the company is unprofitable.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: MDBB.F insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.5%.
Medlab Clinical Limited's company bio, employee growth, exchange listings and data sources
- Name: Medlab Clinical Limited
- Ticker: MDBB.F
- Exchange: OTCPK
- Founded: 2012
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$46.644m
- Listing Market Cap: AU$31.606m
- Shares outstanding: 233.22m
- Website: https://www.medlab.co
Number of Employees
- Medlab Clinical Limited
- 66 McCauley Street
- New South Wales
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|MDC||ASX (Australian Securities Exchange)||Yes||Ordinary Shares||AU||AUD||Jul 2015|
|MDC||CHIA (Chi-X Australia)||Yes||Ordinary Shares||AU||AUD||Jul 2015|
|MDBB.F||OTCPK (Pink Sheets LLC)||Yes||Ordinary Shares||US||USD||Jul 2015|
Medlab Clinical Limited engages in the sale of nutraceutical products, and pharmaceutical research and commercialization in Australia. The company develops bio-therapeutics for bio-therapeutics for chronic kidney diseases, pre-diabetes/obesity, depression, and musculoskeletal muscle loss associated with ageing. It also provides nutraceuticals for anti-inflammatory, cardiovascular support, endocrine support, gastrointestinal support, immunological support, infants and toddlers, metabolic support, musculoskeletal support, neurological support, sports performance, urogenital support, and weight management, as well as for men, pregnancy, seniors, teenagers, and women support. Medlab Clinical Limited was founded in 2012 and is based in Alexandria, Australia.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/06/02 05:34|
|End of Day Share Price||2020/05/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.